Cargando…
When to start and when to stop antifibrotic therapies
Idiopathic pulmonary fibrosis (IPF) is characterised by progressive changes of the lung architecture causing cough and dyspnoea and ultimately leading to lung failure and death. Today, for the first time, two drugs that may reduce the inexorable progression of the disease are available, suggesting t...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
European Respiratory Society
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9488637/ https://www.ncbi.nlm.nih.gov/pubmed/28974541 http://dx.doi.org/10.1183/16000617.0053-2017 |
_version_ | 1784792702766809088 |
---|---|
author | Torrisi, Sebastiano Emanuele Pavone, Mauro Vancheri, Ada Vancheri, Carlo |
author_facet | Torrisi, Sebastiano Emanuele Pavone, Mauro Vancheri, Ada Vancheri, Carlo |
author_sort | Torrisi, Sebastiano Emanuele |
collection | PubMed |
description | Idiopathic pulmonary fibrosis (IPF) is characterised by progressive changes of the lung architecture causing cough and dyspnoea and ultimately leading to lung failure and death. Today, for the first time, two drugs that may reduce the inexorable progression of the disease are available, suggesting that treatment with specific drugs for IPF should be started as soon as diagnosis is made. This applies to any disease and particularly to IPF, which is marked by a 5-year survival comparable or even worse than many cancers. However, despite common sense and even worse, in spite of scientific data coming from clinical trials, post hoc analysis, long-term safety studies and real-life experiences, the question of when to start and when to stop treatment with antifibrotics is still debated. In IPF, particularly when the disease is diagnosed at an early stage, “wait and watch” behaviour is not rare to observe. This is largely due to the lack of awareness of both patients and clinicians regarding the progression of the disease and its prognosis. Another important issue is when treatment should be stopped. In general, there are two main reasons to stop a therapy: unbearable side-effects and/or lack of efficacy. According to current (although preliminary) evidence, antifibrotic drugs should not be discontinued except for safety issues. |
format | Online Article Text |
id | pubmed-9488637 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | European Respiratory Society |
record_format | MEDLINE/PubMed |
spelling | pubmed-94886372022-11-14 When to start and when to stop antifibrotic therapies Torrisi, Sebastiano Emanuele Pavone, Mauro Vancheri, Ada Vancheri, Carlo Eur Respir Rev Reviews Idiopathic pulmonary fibrosis (IPF) is characterised by progressive changes of the lung architecture causing cough and dyspnoea and ultimately leading to lung failure and death. Today, for the first time, two drugs that may reduce the inexorable progression of the disease are available, suggesting that treatment with specific drugs for IPF should be started as soon as diagnosis is made. This applies to any disease and particularly to IPF, which is marked by a 5-year survival comparable or even worse than many cancers. However, despite common sense and even worse, in spite of scientific data coming from clinical trials, post hoc analysis, long-term safety studies and real-life experiences, the question of when to start and when to stop treatment with antifibrotics is still debated. In IPF, particularly when the disease is diagnosed at an early stage, “wait and watch” behaviour is not rare to observe. This is largely due to the lack of awareness of both patients and clinicians regarding the progression of the disease and its prognosis. Another important issue is when treatment should be stopped. In general, there are two main reasons to stop a therapy: unbearable side-effects and/or lack of efficacy. According to current (although preliminary) evidence, antifibrotic drugs should not be discontinued except for safety issues. European Respiratory Society 2017-10-03 /pmc/articles/PMC9488637/ /pubmed/28974541 http://dx.doi.org/10.1183/16000617.0053-2017 Text en Copyright ©ERS 2017. https://creativecommons.org/licenses/by-nc/4.0/ERR articles are open access and distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0. |
spellingShingle | Reviews Torrisi, Sebastiano Emanuele Pavone, Mauro Vancheri, Ada Vancheri, Carlo When to start and when to stop antifibrotic therapies |
title | When to start and when to stop antifibrotic therapies |
title_full | When to start and when to stop antifibrotic therapies |
title_fullStr | When to start and when to stop antifibrotic therapies |
title_full_unstemmed | When to start and when to stop antifibrotic therapies |
title_short | When to start and when to stop antifibrotic therapies |
title_sort | when to start and when to stop antifibrotic therapies |
topic | Reviews |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9488637/ https://www.ncbi.nlm.nih.gov/pubmed/28974541 http://dx.doi.org/10.1183/16000617.0053-2017 |
work_keys_str_mv | AT torrisisebastianoemanuele whentostartandwhentostopantifibrotictherapies AT pavonemauro whentostartandwhentostopantifibrotictherapies AT vancheriada whentostartandwhentostopantifibrotictherapies AT vanchericarlo whentostartandwhentostopantifibrotictherapies |